IMRICOR MEDICAL SYSTEMS INC (IMR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMR

IMR - IMRICOR MEDICAL SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.15
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.82

21 May
2026

0.045

OPEN

$1.80

2.54%

HIGH

$1.83

196,673

LOW

$1.76

TARGET
$2.63 44.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IMR: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 6.7 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-12.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.5 M
Book Value Per Share xxxxxxxxxxxxxxx5.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-29.6 M
Net Profit Margin xxxxxxxxxxxxxxx-8,661.57 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-1,463.63 %
Return on Invested Capital xxxxxxxxxxxxxxx-131.50 %
Return on Assets xxxxxxxxxxxxxxx-75.84 %
Return on Equity xxxxxxxxxxxxxxx-1,463.63 %
Return on Total Capital xxxxxxxxxxxxxxx-89.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-30.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx18 M
Long Term Debt xxxxxxxxxxxxxxx21 M
Total Debt xxxxxxxxxxxxxxx39 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx61 M
Price To Book Value xxxxxxxxxxxxxxx28.42

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.7 M
Capex % of Sales xxxxxxxxxxxxxxx148.57 %
Cost of Goods Sold xxxxxxxxxxxxxxx4 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx32 M
Research & Development xxxxxxxxxxxxxxx17 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

29/04/2026

1

Speculative Buy

$2.63

44.51%

Imricor Medical Systems reported net operating cash flow of US$7.8m for the first quarter. Morgans notes, while sales remain modest, the underlying cash burn was higher than the prior quarter and is expected to normalise at around -US$6m.

During the quarter costs, albeit one-off, related to the purchase of 40 generators that are part of an in-house transition process.

The broker makes no changes to forecasts but a higher risk-free rate means the valuation, hence target, is reduced to $2.63 from $2.71. Speculative Buy rating maintained as numerous catalysts approach.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -6.69 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -4.76 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

19/05/2026

1

Buy

$2.28

25.27%

Canaccord Genuity maintains a Buy rating for Imricor Medical Systems with its target price lowered to $2.28 from $2.33 following the completion of a US$43m capital raise.

The funding round bolsters pro forma cash to US$74m and introduces -2.7% dilution compared to previous estimates.

The broker expects early commercial wins in the United States, anticipating the first sales for the NorthStar system will occur within the paediatric hospital setting.

Upcoming milestones for the third quarter of 2026 include the completion of the VISABL-AFL trial, FDA submission, and initial integration with GE magnetic resonance imaging units.

Feedback from industry specialists suggests strong potential for off-label use in complex procedures, leading the broker to view a 2027 industry conference as a major inflection point for adoption.

Taylor Collison

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

(xx/xx/xxxx)

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

IMR STOCK CHART

FNArena News on IMR

1
In Brief: Imricor, COG Financial & Alicantro

10:00 AM - Weekly Reports
2
Australian Broker Call *Extra* Edition – May 21, 2026

May 21 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – May 19, 2026

May 19 2026 - Daily Market Reports
4
Next Week At A Glance – 4-8 May 2026

May 01 2026 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Mar 05, 2026

Mar 05 2026 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
2
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
3
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
4
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
5
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
6
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
7
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
8
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
9
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
10
ResMed’s New Level Of Support

Jul 29 2025 - Technicals